Filtered By:
Condition: Heart Attack
Vaccination: Vaccines
This page shows you your search results in order of relevance. This is page number 4.
Order by Relevance | Date
Total 175 results found since Jan 2013.
Association between Influenza Vaccination and Reduced Risks of Major Adverse Cardiovascular Events in Elderly Patients
Conclusions Results of this study suggest that influenza vaccination is associated with reduced primary MACE risks in the elderly population, including those with ILI.
Source: American Heart Journal - August 2, 2017 Category: Cardiology Source Type: research
Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profile backed by ove...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Comparative Safety of BNT162b2 and mRNA-1273 Vaccines in a Nationwide Cohort of US Veterans
CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there were few differences in risk of adverse events within 14 days of the first dose of either the BNT162b2 or the mRNA-1273 vaccine and small-magnitude differences within 42 days of the first dose. The 38-week risks of adverse events were low in both vaccine groups, although risks were lower for recipients of the mRNA-1273 vaccine than for recipients of the BNT162b2 vaccine. Although the primary analysis was designed to detect safety events unrelated to SARS-CoV-2 infection, the possibility that these differences may partially be explained by a low...
Source: Herpes - June 13, 2022 Category: Infectious Diseases Authors: Barbra A Dickerman Arin L Madenci Hanna Gerlovin Katherine E Kurgansky Jessica K Wise Michael J Figueroa Mu ñiz Brian R Ferolito David R Gagnon J Michael Gaziano Kelly Cho Juan P Casas Miguel A Hern án Source Type: research
Major acute cardiovascular events after dengue infection –A population-based observational study
ConclusionsThe risks for MACEs are significantly higher in the immediate time period after dengue infection. Since dengue infection is potentially preventable by early recognition and vaccination, the dengue-associated MACE should be taken into consideration when making public health management policies.
Source: PLoS Neglected Tropical Diseases - February 7, 2022 Category: Tropical Medicine Authors: Kai-Che Wei Source Type: research
Adverse events following COVID ‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia
ConclusionAvailable literature includes more studies with the BNT162b2 vaccine than mRNA-1273. Future studies must report mortality and adverse cardiovascular events by vaccine types.
Source: Immunity, Inflammation and Disease - March 17, 2023 Category: Allergy & Immunology Authors: Farah Yasmin,
Hala Najeeb,
Unaiza Naeem,
Abdul Moeed,
Abdul Raafe Atif,
Muhammad Sohaib Asghar,
Nayef Nimri,
Maryam Saleem,
Dhrubajyoti Bandyopadhyay,
Chayakrit Krittanawong,
Mohammed Mahmmoud Fadelallah Eljack,
Muhammad Junaid Tahir,
Fahad Wa Tags: REVIEW ARTICLE Source Type: research
Impact of influenza, herpes zoster, and pneumococcal vaccinations on the incidence of cardiovascular events in subjects aged over 65 years: a systematic review
Geroscience. 2023 Jun 3. doi: 10.1007/s11357-023-00807-4. Online ahead of print.ABSTRACTThis systematic review aims to summarize the impact of vaccination against influenza, shingles, and pneumococcus on the incidence on the risk of cardiovascular events in the elderly. This protocol was developed in accordance with PRISMA guidelines. We conducted a literature search and identified all relevant articles published regarding the matter up to September 2022. We retrieved 38 studies (influenza vaccine = 33, pneumococcal vaccine = 5, and zoster vaccine = 2). A total of 28 and 2 studies have shown that influenza and pneumococcal...
Source: Herpes - June 3, 2023 Category: Infectious Diseases Authors: Alexandra Addario Thomas C élarier Bienvenu Bongue Nathalie Barth Ga ëtan Gavazzi Elisabeth Botelho-Nevers Source Type: research
Vegetarians have 'poorer quality of life' study claims
Conclusion
Despite the media headlines, the results from this Austrian cross sectional survey provide no proof that vegetarians are in poorer health than meat eaters.
The study has simply compared a group of people with a “vegetarian” diet with three different groups of people following “carnivorous” diets on a range of different health and lifestyle measures to see if any differences are observed.
The study has numerous limitations:
The cross sectional study cannot prove cause and effect and that the dietary pattern is responsible for any of these self-reported differences. In fact it is possible the associat...
Source: NHS News Feed - April 4, 2014 Category: Consumer Health News Tags: Food/diet Lifestyle/exercise Mental health Source Type: news
10 Good Reasons To Get A Flu Shot
By Melaina Juntti for Men's Journal
How many times have you heard you should get a flu shot? There's good reason for the hype: Over the past few years, the influenza vaccine has prevented millions of flu cases and tens of thousands of related hospitalizations, according to Centers for Disease Control and Prevention.
Although an increasing number of people are getting vaccinated every year, more than half of American men still aren't doing it, for a variety of reasons, most of which aren't backed by science. "Men have this macho sense that if they do get the flu, they can tough it out," says William Schaffner, M.D., chair...
Source: Science - The Huffington Post - November 29, 2014 Category: Science Source Type: news
Get the flu vaccine, reduce your risk of death
Last year was a lousy year for the flu vaccine. Hospitalizations for flu hit a nine-year high, and the vaccine prevented flu in only 23% of all recipients, compared with 50% to 60% of recipients in prior years.
Why does the flu vaccine work well in some winters and not others? The flu vaccine primes the immune system to attack two proteins on the surface of the influenza A virus, hemagglutinin (H) and neuraminidase (N). Different flu strains have different combinations of these proteins — for example, the strains targeted by recent flu vaccines are H3N2 and H1N1.
Unfortunately, the influenza virus is microbiology’s ans...
Source: New Harvard Health Information - September 15, 2015 Category: Consumer Health News Authors: John Ross, MD, FIDSA Tags: Cold and Flu Vaccines Flu Shot flu vaccine Source Type: news
Will a cholesterol-busting vaccine work for humans?
Conclusion
The first thing to keep in mind is this is an early-stage study in the development of a vaccine to lower cholesterol. The study found some of the experimental vaccines the researchers developed had an effect on the cholesterol levels of mice and monkeys to varying degrees.
They now need to do further work to show the vaccine is effective and can be used safely in humans. Many drugs have very different effects in humans than they do in other animals.
The use of statins to lower cholesterol and reduce the chances of a heart attack or stroke is well established and effective for many people. Although there is ongo...
Source: NHS News Feed - November 12, 2015 Category: Consumer Health News Tags: Heart/lungs Medication Source Type: news
A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale.
CONCLUSIONS: This high-dose influenza vaccine trial uniquely offers a paradigm for future studies of clinical and programmatic interventions within the framework of efforts designed to test the impact of changes in usual treatment practices adopted by health care systems.
TRIAL REGISTRATION: NCT01815268.
PMID: 26908539 [PubMed - as supplied by publisher]
Source: Clinical Trials - February 11, 2016 Category: Research Authors: Gravenstein S, Dahal R, Gozalo PL, Davidson HE, Han LF, Taljaard M, Mor V Tags: Clin Trials Source Type: research
